Microdiversity Predicts Outcome in Children's Kidney Cancer
|
By LabMedica International staff writers Posted on 08 Feb 2015 |

Image: CT Scan of 11-centimeter Wilms' tumor of the right kidney in a 13-month-old patient (Photo courtesy of Wikimedia Commons).
A prognosis for the outcome of Wilms' tumor, the most common type of kidney cancer in children, can be determined by examining the genetic variation in a biopsy specimen as small as one millimeter in diameter.
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Latest Pathology News
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







